Skip to main content

Immunobiology and immunotherapy

Section edited by Alessandra Cesano

This section aims to enrich the communication between basic biological and immunological sciences and the clinical investigation arena.

As immunology has evolved to be a central discipline connected to a wide range of therapeutic areas, the number and diversity of platform technologies has also increased, spanning small molecules, biologics, microbial vectors and cells. Such levels of activity require appropriate means to share new knowledge and to catalyze the development of the field. This section aims to provide such a platform and welcomes submissions across all disciplines, including inflammation, autoimmunity, transplantation, metabolic disorders.

The section was founded with the Society for Immunotherapy of Cancer (SITC) under the title "Tumor immunology and biological cancer therapy" and Edited by Pedro Romero.

Page 7 of 9

  1. Alveolar soft part sarcoma (ASPS) is a rare soft tissue sarcoma and the clinical management of patients with unresectable, metastatic disease is still challenging. ASPS expresses an array of potentially therap...

    Authors: Chiara Castelli, Marcella Tazzari, Tiziana Negri, Barbara Vergani, Licia Rivoltini, Silvia Stacchiotti and Silvana Pilotti
    Citation: Journal of Translational Medicine 2013 11:237
  2. Resistin increases during several inflammatory diseases and after intracerebral bleeding or head trauma. Resistin activates the endothelium and may initiate an inflammatory response. No data are available on r...

    Authors: Simona Oltean, Rille Pullerits, Anne Flodén, Michael Olausson and Mihai Oltean
    Citation: Journal of Translational Medicine 2013 11:233
  3. Primary cutaneous lymphomas (CLs), characterized by an accumulation of clonal T or B lymphocytes preferentially localized in the skin, have been successfully treated with interferons (IFNs) which counterbalanc...

    Authors: Nathalie Accart, Mirjana Urosevic-Maiwald, Reinhard Dummer, Vincent Bataille, Nadine Kehrer, Cristina Niculescu, Jean-Marc Limacher, Marie-Pierre Chenard, Jean-Yves Bonnefoy and Ronald Rooke
    Citation: Journal of Translational Medicine 2013 11:226
  4. Antibodies binding to citrullinated proteins are a frequent finding in rheumatoid arthritis patients and may precede the onset of clinical symptoms several years. The antibodies are a predisposing factor for b...

    Authors: Sanna Turunen, Marja-Kaisa Koivula, Jukka Melkko, Eeva Alasaarela, Petri Lehenkari and Juha Risteli
    Citation: Journal of Translational Medicine 2013 11:224
  5. Targeted therapies directed at commonly overexpressed pathways in melanoma have clinical activity in numerous trials. Little is known about how these therapies influence microRNA (miRNA) expression, particular...

    Authors: Aubrey G Wagenseller, Amber Shada, Kevin M D’Auria, Cheryl Murphy, Dandan Sun, Kerrington R Molhoek, Jason A Papin, Anindya Dutta and Craig L Slingluff Jr
    Citation: Journal of Translational Medicine 2013 11:218
  6. T-cell immunoglobulin and mucin domain 3 (TIM-3) is known as a negative immune regulator and emerging data have implicated TIM-3 a pivotal role in suppressing antitumor immunity. The co-stimulatory receptor CD...

    Authors: Zhiqiang Guo, Dali Cheng, Zhijun Xia, Meng Luan, Liangliang Wu, Gang Wang and Shulan Zhang
    Citation: Journal of Translational Medicine 2013 11:215
  7. Ultraviolet-inactivated, replication-defective Sendai virus particles (Z strain) have displayed antitumor effect through enhancing the immune responses or inducing apoptosis in a variety of carcinomas. Sendai ...

    Authors: Liying Shi, Jun Chen, Qiping Zhong, Mei Li, Peng Geng, Jianmin He, Zhe Han, Mingwei Sheng and Hua Tang
    Citation: Journal of Translational Medicine 2013 11:205
  8. Malignant pleural mesothelioma (MPM) is an incurable malignant disease, which results from chronic exposition to asbestos in at least 70% of the cases. Fibroblast activation protein (FAP) is predominantly expr...

    Authors: Petra C Schuberth, Christian Hagedorn, Shawn M Jensen, Pratiksha Gulati, Maries van den Broek, Axel Mischo, Alex Soltermann, Astrid Jüngel, Osiris Marroquin Belaunzaran, Rolf Stahel, Christoph Renner and Ulf Petrausch
    Citation: Journal of Translational Medicine 2013 11:187
  9. Natural killer (NK) cells can kill tumor cells in a non-MHC-restricted manner. However, cancer cells frequently escape from the attack of NK cells by multiple ways. In this study, we investigated the effect of...

    Authors: Sisi He, Tao Yin, Dan Li, Xiang Gao, Yang Wan, Xuelei Ma, Tinghong Ye, Fuchun Guo, Jianhong Sun, Ziqiang Lin and Yongsheng Wang
    Citation: Journal of Translational Medicine 2013 11:186
  10. mRNA electroporation of dendritic cells (DCs) facilitates processing and presentation of multiple peptides derived from whole antigen, tailored to different HLA molecules. Clinical responses to electroporated ...

    Authors: David J Chung, Emanuela Romano, Katherine B Pronschinske, Justin A Shyer, Milena Mennecozzi, Erin T St Angelo and James W Young
    Citation: Journal of Translational Medicine 2013 11:166
  11. New treatment modalities are needed for the treatment of cancers of the head and neck region (HNSCC). Survivin is important for the survival and proliferation of tumor cells and may therefore provide a target ...

    Authors: Annelies W Turksma, Hetty J Bontkes, Janneke J Ruizendaal, Kirsten BJ Scholten, Johanneke Akershoek, Shakila Rampersad, Laura M Moesbergen, Saskia AGM Cillessen, Saskia JAM Santegoets, Tanja D de Gruijl, C René Leemans, Chris JLM Meijer and Erik Hooijberg
    Citation: Journal of Translational Medicine 2013 11:152
  12. A promising cancer vaccine involves the fusion of tumor cells with dendritic cells (DCs). As such, a broad spectrum of both known and unidentified tumor antigens is presented to the immune system in the contex...

    Authors: Chunrui Tan, Varun Reddy, Jens Dannull, Enyu Ding, Smita K Nair, Douglas S Tyler, Scott K Pruitt and Walter T Lee
    Citation: Journal of Translational Medicine 2013 11:148
  13. In cancer immunotherapy, dendritic cells (DCs) play a fundamental role in the dialog between innate and adaptive immune response, but several immunosuppressive mechanisms remain to be overcome. For example, a ...

    Authors: Laura Ridolfi, Massimiliano Petrini, Anna Maria Granato, Giusy Gentilcore, Ester Simeone, Paolo Antonio Ascierto, Elena Pancisi, Valentina Ancarani, Laura Fiammenghi, Massimo Guidoboni, Francesco de Rosa, Linda Valmorri, Emanuela Scarpi, Stefania Vittoria Luisa Nicoletti, Stefano Baravelli, Angela Riccobon…
    Citation: Journal of Translational Medicine 2013 11:135
  14. Deceased after cardiac arrest donor are an additional source of kidney graft to overcome graft shortage. Deciphering the respective role of renal warm and cold ischemia is of pivotal interest in the transplant...

    Authors: Ludivine Rossard, Frédéric Favreau, Sebastien Giraud, Raphael Thuillier, Sylvain Le Pape, Jean Michel Goujon, Alexandre Valagier and Thierry Hauet
    Citation: Journal of Translational Medicine 2013 11:129
  15. Generation of tolerogenic dendritic cells (TolDCs) for therapy is challenging due to its implications for the design of protocols suitable for clinical applications, which means not only using safe products, b...

    Authors: Paulina García-González, Rodrigo Morales, Lorena Hoyos, Jaxaira Maggi, Javier Campos, Bárbara Pesce, David Gárate, Milton Larrondo, Rodrigo González, Lilian Soto, Verónica Ramos, Pía Tobar, María Carmen Molina, Karina Pino-Lagos, Diego Catalán and Juan Carlos Aguillón
    Citation: Journal of Translational Medicine 2013 11:128
  16. Primary testicular lymphoma (PTL) is a rare and lethal disease. The most common histological subtype is diffuse large B-cell lymphoma (DLBCL). Standard treatments are frequently ineffective. Thus, the developm...

    Authors: Tvrtko Hudolin, Zeljko Kastelan, Ivana Ilic, Katarina Levarda-Hudolin, Nikolina Basic-Jukic, Malte Rieken, Giulio C Spagnoli, Antonio Juretic and Chantal Mengus
    Citation: Journal of Translational Medicine 2013 11:123
  17. CTLA-4 (Cytotoxic T lymphocyte antigen-4) is traditionally known as a negative regulator of T cell activation. The blocking of CTLA-4 using human monoclonal antibodies, such as Ipilimumab, is currently used to...

    Authors: Stefania Laurent, Paola Queirolo, Silvia Boero, Sandra Salvi, Patrizia Piccioli, Simona Boccardo, Simona Minghelli, Anna Morabito, Vincenzo Fontana, Gabriella Pietra, Paolo Carrega, Nicoletta Ferrari, Francesca Tosetti, Lung-Ji Chang, Maria Cristina Mingari, Guido Ferlazzo…
    Citation: Journal of Translational Medicine 2013 11:108
  18. Malignant pleural effusion (MPE) is associated with advanced stages of lung cancer and is mainly dependent on invasion of the pleura and expression of vascular endothelial growth factor (VEGF) by cancer cells....

    Authors: Stephanie Weibel, Elisabeth Hofmann, Thomas Christian Basse-Luesebrink, Ulrike Donat, Carolin Seubert, Marion Adelfinger, Prisca Gnamlin, Christina Kober, Alexa Frentzen, Ivaylo Gentschev, Peter Michael Jakob and Aladar A Szalay
    Citation: Journal of Translational Medicine 2013 11:106
  19. Vaccine treatment using multiple peptides derived from multiple proteins is considered to be a promising option for cancer immune therapy, but scientific evidence supporting the therapeutic efficacy of multipl...

    Authors: Hiroyuki Suzuki, Mitsuro Fukuhara, Takumi Yamaura, Satoshi Mutoh, Naoyuki Okabe, Hiroshi Yaginuma, Takeo Hasegawa, Atsushi Yonechi, Jun Osugi, Mika Hoshino, Takashi Kimura, Mitsunori Higuchi, Yutaka Shio, Kazuya Ise, Kazuyoshi Takeda and Mitsukazu Gotoh
    Citation: Journal of Translational Medicine 2013 11:97
  20. The FDA recently approved an anti-CTLA-4 antibody (Iplimumab) for the treatment of metastatic melanoma. This decision was based on Phase III results, which demonstrate that blocking this immune checkpoint prov...

    Authors: Satoshi Wada, Christopher M Jackson, Kiyoshi Yoshimura, Hung-Rong Yen, Derese Getnet, Timothy J Harris, Monica V Goldberg, Tullia C Bruno, Joseph F Grosso, Nicholas Durham, George J Netto, Drew M Pardoll and Charles G Drake
    Citation: Journal of Translational Medicine 2013 11:89
  21. The number of immune cells, especially dendritic cells and cytotoxic tumor infiltrating lymphocytes (TIL), particularly Th1 cells, CD8 T cells, and NK cells is associated with increased survival of cancer pati...

    Authors: Jingting Jiang, Changping Wu and Binfeng Lu
    Citation: Journal of Translational Medicine 2013 11:83
  22. Despite availability of efficient treatment regimens for early stage colorectal cancer, treatment regimens for late stage colorectal cancer are generally not effective and thus need improvement. Oncolytic viro...

    Authors: Klaas Ehrig, Mehmet O Kilinc, Nanhai G Chen, Jochen Stritzker, Lisa Buckel, Qian Zhang and Aladar A Szalay
    Citation: Journal of Translational Medicine 2013 11:79
  23. CD8+ T cells are key members of adaptive immunity against tumorigenesis. As subset of CD8+ T cells, effector T cells (Te) and memory T cells (Tm) have different biological activities. The former can kill tumor...

    Authors: Guocheng Zhong, Xiaoming Cheng, Haixia Long, Luhang He, Wei Qi, Tong Xiang, Zhongquan Zhao and Bo Zhu
    Citation: Journal of Translational Medicine 2013 11:71
  24. L-BLP25 antigen-specific cancer immunotherapeutic agent is currently in phase III clinical trials for non-small cell lung cancer. Using a novel human MUC1 transgenic (hMUC1.Tg) lung cancer mouse model, we eval...

    Authors: Gregory T Wurz, Audrey M Gutierrez, Brittany E Greenberg, Daniel P Vang, Stephen M Griffey, Chiao-Jung Kao, Michael Wolf and Michael W DeGregorio
    Citation: Journal of Translational Medicine 2013 11:64
  25. Imatinib mesylate is an effective treatment for metastatic gastrointestinal stromal tumor (GIST). However, most patients eventually develop resistance and there are few other treatment options. Immunotherapy u...

    Authors: Steven C Katz, Rachel A Burga, Seema Naheed, Lauren A Licata, Mitchell Thorn, Doreen Osgood, Cang T Nguyen, N Joseph Espat, Jonathan A Fletcher and Richard P Junghans
    Citation: Journal of Translational Medicine 2013 11:46
  26. The sixth leading class of cancer worldwide is head and neck cancer, which typically arise within the squamous epithelium of the oral mucosa. Human head and neck squamous cell carcinoma (HNSCC) is known to be ...

    Authors: Bradford Hall, Hideyuki Nakashima, Zhi-Jun Sun, Yuki Sato, Yansong Bian, Syed R Husain, Raj K Puri and Ashok B Kulkarni
    Citation: Journal of Translational Medicine 2013 11:45
  27. Besides being a preferential site of early metastasis, the sentinel lymph node (SLN) is also a privileged site of T-cell priming, and may thus be an appropriate target for investigating cell types involved in ...

    Authors: Anita Mohos, Tímea Sebestyén, Gabriella Liszkay, Vanda Plótár, Szabolcs Horváth, István Gaudi and Andrea Ladányi
    Citation: Journal of Translational Medicine 2013 11:43
  28. Adoptive cell transfer of tumor infiltrating lymphocytes has shown clinical efficacy in the treatment of melanoma and is now also being explored in other tumor types. Generation of sufficient numbers of effect...

    Authors: Saskia JAM Santegoets, Annelies W Turksma, Megan M Suhoski, Anita GM Stam, Steve M Albelda, Erik Hooijberg, Rik J Scheper, Alfons JM van den Eertwegh, Winald R Gerritsen, Daniel J Powell Jr, Carl H June and Tanja D de Gruijl
    Citation: Journal of Translational Medicine 2013 11:37
  29. Hirsutanol A is a novel sesquiterpene compound purified from fungus Chondrostereum sp. in Sarcophyton tortuosum. Our previous studies had demonstrated that hirsutanol A exhibited potent cytotoxic effect on many k...

    Authors: Fen Yang, Wen-Dan Chen, Rong Deng, Hui Zhang, Jun Tang, Ke-Wei Wu, Dan-Dan Li, Gong-Kan Feng, Wen-Jian Lan, Hou-Jin Li and Xiao-Feng Zhu
    Citation: Journal of Translational Medicine 2013 11:32
  30. MicroRNAs (miRNAs) are small (19-22-nt) single-stranded noncoding RNA molecules whose deregulation of expression can contribute to human disease including the multistep processes of carcinogenesis in human. Ci...

    Authors: Hussein Fayyad-Kazan, Nizar Bitar, Mehdi Najar, Philippe Lewalle, Mohammad Fayyad-Kazan, Rabih Badran, Eva Hamade, Ahmad Daher, Nader Hussein, Rim ELDirani, Fadwa Berri, Luc Vanhamme, Arsène Burny, Philippe Martiat, Redouane Rouas and Bassam Badran
    Citation: Journal of Translational Medicine 2013 11:31
  31. Natural Killer (NK) cells are known to reject several experimental murine tumors, but their antineoplastic activity in humans is not generally agreed upon, as exemplified by an interesting correspondence recen...

    Authors: Doriana Fruci, Elisa Lo Monaco, Loredana Cifaldi, Franco Locatelli, Elisa Tremante, Maria Benevolo and Patrizio Giacomini
    Citation: Journal of Translational Medicine 2013 11:30
  32. Chimeric Antigen Receptors (CARs) consist of the antigen-recognition portion of a monoclonal antibody fused to an intracellular signaling domain capable of activating T-cells. CARs displayed on the surface of ...

    Authors: Satiro N De Oliveira, Jiexin Wang, Christine Ryan, Sherie L Morrison, Donald B Kohn and Roger P Hollis
    Citation: Journal of Translational Medicine 2013 11:23
  33. EMD 521873 (Selectikine or NHS-IL2LT) is a fusion protein consisting of modified human IL-2 which binds specifically to the high-affinity IL-2 receptor, and an antibody specific for both single- and double-str...

    Authors: Julien Laurent, Cedric Touvrey, Silke Gillessen, Magali Joffraud, Manuela Vicari, Caroline Bertrand, Stefano Ongarello, Bernd Liedert, Elisa Gallerani, Joachim Beck, Aurelius Omlin, Cristiana Sessa, Sonia Quaratino, Roger Stupp, Ulrike S Gnad-Vogt and Daniel E Speiser
    Citation: Journal of Translational Medicine 2013 11:5
  34. Multiple myeloma (MM) is a plasma cell malignancy with a multifaceted immune dysfunction. Indoleamine 2,3-dioxygenase 1 (IDO1) degrades tryptophan into kynurenine (KYN), which inhibits effector T cells and pro...

    Authors: Giuseppina Bonanno, Andrea Mariotti, Annabella Procoli, Valentina Folgiero, Daniela Natale, Luca De Rosa, Ignazio Majolino, Linda Novarese, Alberto Rocci, Manuela Gambella, Marilena Ciciarello, Giovanni Scambia, Antonio Palumbo, Franco Locatelli, Raimondo De Cristofaro and Sergio Rutella
    Citation: Journal of Translational Medicine 2012 10:247
  35. Multiple farnesylated proteins are involved in signal transduction in cancer. Farnesyltransferase inhibitors (FTIs) have been developed as a strategy to inhibit the function of these proteins. As FTIs inhibit ...

    Authors: Thomas F Gajewski, April KS Salama, Donna Niedzwiecki, Jeffrey Johnson, Gerald Linette, Cynthia Bucher, Michelle A Blaskovich, Said M Sebti and Frank Haluska
    Citation: Journal of Translational Medicine 2012 10:246
  36. CTLA4 blocking monoclonal antibodies provide a low frequency but durable tumor responses in patients with metastatic melanoma, which led to the regulatory approval of ipilimumab based on two randomized clinica...

    Authors: Antoni Ribas, Jason A Chesney, Michael S Gordon, Amy P Abernethy, Theodore F Logan, David H Lawson, Bartosz Chmielowksi, John A Glaspy, Karl Lewis, Bo Huang, Erjian Wang, Poe-Hirr Hsyu, Jesus Gomez-Navarro, Diana Gerhardt, Margaret A Marshall and Rene Gonzalez
    Citation: Journal of Translational Medicine 2012 10:236
  37. Anti-EGFR monoclonal antibodies have shown efficacy in the treatment of metastatic colorectal cancer (mCRC). One of the mechanism is the antibody-dependent cell-mediated cytotoxicity (ADCC) in which Fc region ...

    Authors: Rosa Calemma, Alessandro Ottaiano, Anna Maria Trotta, Guglielmo Nasti, Carmela Romano, Maria Napolitano, Domenico Galati, Pasquale Borrelli, Serena Zanotta, Antonino Cassata, Giuseppe Castello, Vincenzo Rosario Iaffaioli and Stefania Scala
    Citation: Journal of Translational Medicine 2012 10:232
  38. High-intensity focused-ultrasound (HIFU) has been successfully employed for thermal ablation of tumors in clinical settings. Continuous- or pulsed-mode HIFU may also induce a host antitumor immune response, ma...

    Authors: Hao-Li Liu, Han-Yi Hsieh, Li-An Lu, Chiao-Wen Kang, Ming-Fang Wu and Chun-Yen Lin
    Citation: Journal of Translational Medicine 2012 10:221
  39. Trifunctional bispecific antibodies (trAb) are a special class of bispecific molecules recruiting and activating T cells and accessory immune cells simultaneously at the targeted tumor. The new trAb Ektomab th...

    Authors: Peter Ruf, Beatrix Schäfer, Nina Eissler, Ralph Mocikat, Juergen Hess, Matthias Plöscher, Susanne Wosch, Ivonne Suckstorff, Christine Zehetmeier and Horst Lindhofer
    Citation: Journal of Translational Medicine 2012 10:219
  40. Trastuzumab is currently approved for the clinical treatment of breast and gastric cancer patients with HER-2 positive tumors, but not yet for the treatment of esophageal carcinoma patients, whose tumors typic...

    Authors: Xianhua Wu, Jingchuan Zhang, Ruheng Zhen, Jing Lv, Li Zheng, Xinying Su, Guanshan Zhu, Paul R Gavine, Songtao Xu, Shaohua Lu, Jun Hou, Yalan Liu, Chen Xu, Yunshan Tan, Liang Xie, Xiaolu Yin…
    Citation: Journal of Translational Medicine 2012 10:180
  41. Adoptive cell therapy may be based on isolation of tumor-specific T cells, e.g. autologous tumor infiltrating lymphocytes (TIL), in vitro activation and expansion and the reinfusion of these cells into patient...

    Authors: Eva Ellebaek, Trine Zeeberg Iversen, Niels Junker, Marco Donia, Lotte Engell-Noerregaard, Özcan Met, Lisbet Rosenkrantz Hölmich, Rikke Sick Andersen, Sine Reker Hadrup, Mads Hald Andersen, Per thor Straten and Inge Marie Svane
    Citation: Journal of Translational Medicine 2012 10:169
  42. DepoVaxTM is a novel non-emulsion depot-forming vaccine platform with the capacity to significantly enhance the immunogenicity of peptide cancer antigens. Naturally processed HLA-A2 restricted peptides presented ...

    Authors: Neil L Berinstein, Mohan Karkada, Michael A Morse, John J Nemunaitis, Gurkamal Chatta, Howard Kaufman, Kunle Odunsi, Rita Nigam, Leeladhar Sammatur, Lisa D MacDonald, Genevieve M Weir, Marianne M Stanford and Marc Mansour
    Citation: Journal of Translational Medicine 2012 10:156
  43. Present immunoprevention and immunotherapeutic approaches against cancer suffer from the limitation of being not “sterilizing” procedures, as very poor protection against the tumor is obtained. Thus newly conc...

    Authors: Roberto S Accolla and Giovanna Tosi
    Citation: Journal of Translational Medicine 2012 10:154
  44. Myeloid-derived Suppressor Cells (MDSC) have been identified as tumor-induced immature myeloid cells (IMC) with potent immune suppressive activity in cancer. Whereas strict phenotypic classification of MDSC ha...

    Authors: Lauren P Virtuoso, Jamie L Harden, Paula Sotomayor, Wade J Sigurdson, Fuminobu Yoshimura, Nejat K Egilmez, Boris Minev and Mehmet O Kilinc
    Citation: Journal of Translational Medicine 2012 10:152
  45. Since a phase I clinical trial using three HLA-A24-binding peptides from TTK protein kinase (TTK), lymphocyte antigen-6 complex locus K (LY6K), and insulin-like growth factor-II mRNA binding protein-3 (IMP3) h...

    Authors: Koji Kono, Hisae Iinuma, Yasunori Akutsu, Hiroaki Tanaka, Naoko Hayashi, Yasuto Uchikado, Tsuyoshi Noguchi, Hideki Fujii, Kota Okinaka, Ryoji Fukushima, Hisahiro Matsubara, Masaichi Ohira, Hideo Baba, Shoji Natsugoe, Seigou Kitano, Kazuyoshi Takeda…
    Citation: Journal of Translational Medicine 2012 10:141
  46. HIV-negative, CD20-negative de novo diffuse large B-cell lymphoma (DLBCL) patients has rarely been reported. To elucidate the nature of this entity, we retrospectively reviewed the data of 1,456 consecutive de no...

    Authors: Ya-Jun Li, Zhi-Ming Li, Hui-Lan Rao, Yi Xia, Hui-Qiang Huang, Zhong-Jun Xia, Su Li, Wen-Yu Li and Wen-Qi Jiang
    Citation: Journal of Translational Medicine 2012 10:84
  47. To date very few systems have been described for preclinical investigations of human cellular therapeutics in vivo. However, the ability to carry out comparisons of new cellular vaccines in vivo would be of subst...

    Authors: Stefani Spranger, Bernhard Frankenberger and Dolores J Schendel
    Citation: Journal of Translational Medicine 2012 10:30
  48. Patients with HER2-overexpressing metastatic breast cancer, despite initially benefiting from the monoclonal antibody trastuzumab and the EGFR/HER2 tyrosine kinase inhibitor lapatinib, will eventually have pro...

    Authors: Erika Hamilton, Kimberly Blackwell, Amy C Hobeika, Timothy M Clay, Gloria Broadwater, Xiu-Rong Ren, Wei Chen, Henry Castro, Frederic Lehmann, Neil Spector, Junping Wei, Takuya Osada and H Kim Lyerly
    Citation: Journal of Translational Medicine 2012 10:28

    The Erratum to this article has been published in Journal of Translational Medicine 2013 11:82

  49. It is widely accepted that systemic neoplastic spread is a late event in tumour progression. However, sometimes, rapidly invasive cancers are diagnosed because of appearance of metastatic lesions in absence of...

    Authors: Giulia Maria Stella, Rebecca Senetta, Adele Cassenti, Margherita Ronco and Paola Cassoni
    Citation: Journal of Translational Medicine 2012 10:12

Annual Journal Metrics